Generative Artificial Intelligence (AI) In Drug Discovery Global Market Report 2026

Description

Generative AI in drug discovery involves the use of advanced machine learning, particularly generative models, to create and identify new pharmaceutical compounds. These AI systems analyze extensive datasets, including chemical properties, biological activity, and existing drug information, to predict and generate novel molecules with potential therapeutic benefits. The primary objective of generative AI in drug discovery is to accelerate the development and identification of novel pharmaceutical compounds with potential therapeutic effects while optimizing the drug development process through data-driven prediction and efficient molecule generation.

The primary types of generative artificial intelligence (AI) in drug discovery are small molecules and large molecules. Small molecules are drugs that are chemically synthesized and typically have a low molecular weight. The technologies include deep learning, machine learning, reinforcement learning, molecular docking, and quantum computing, which are used by various end users, including pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations (CROs), and others.

Tariffs are influencing the generative artificial intelligence in drug discovery market by increasing costs associated with imported computing infrastructure, specialized hardware, and software platforms. Pharmaceutical and biotechnology companies are particularly affected because of their reliance on high-performance imported systems. These tariffs are increasing research expenses and may constrain technology adoption, while also encouraging domestic AI technology development and greater investment in localized solutions.

The generative artificial intelligence (AI) in drug discovery market research report is one of a series of new reports from The Business Research Company that provides generative artificial intelligence (AI) in drug discovery market statistics, including generative artificial intelligence (AI) in drug discovery industry global market size, regional shares, competitors with a generative artificial intelligence (AI) in drug discovery market share, detailed generative artificial intelligence (AI) in drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the generative artificial intelligence (AI) in drug discovery industry. This generative artificial intelligence (AI) in drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The generative artificial intelligence (AI) in drug discovery market size has grown exponentially in recent years. It will grow from $0.25 billion in 2025 to $0.33 billion in 2026 at a compound annual growth rate (CAGR) of 31.2%. The growth during the historic period can be attributed to high drug development costs, advancements in computational chemistry, increasing availability of biological datasets, adoption of machine learning tools, and rising pharmaceutical R&D investment.

The generative artificial intelligence (AI) in drug discovery market size is expected to see exponential growth in the next few years. It will grow to $0.87 billion in 2030 at a compound annual growth rate (CAGR) of 27.2%. The growth during the forecast period can be attributed to the integration of generative models into drug discovery pipelines, increasing demand for faster drug discovery processes, expansion of biologics optimization, growing collaboration between AI companies and pharmaceutical firms, and reduced time-to-market. Key trends during the forecast period include rising adoption of AI-driven molecule generation, increased use of deep learning in drug design, expansion of small molecule discovery applications, greater integration of AI into lead optimization, and accelerated early-stage drug development.

The rising number of clinical trials is expected to propel the growth of generative AI in the drug discovery market. Clinical trials involve human volunteers to evaluate the safety and effectiveness of new medical treatments or procedures and generate scientific evidence regarding their suitability for human use. The increasing number of clinical trials is primarily driven by advancements in medical research, the growing disease burden, regulatory changes, globalization of clinical research, increased patient advocacy and awareness, industry competition, technological advancements, and greater funding opportunities. Clinical trial data provides valuable inputs for generative AI models, accelerating drug discovery by predicting molecular interactions and designing new compounds. This combination supports personalized medicine, optimizes treatment effectiveness, improves patient outcomes, and transforms the pharmaceutical landscape. For instance, in January 2025, according to Pharmaceutical Technology, a UK-based business news and media company, 3,213 trials were planned to start in 2025, including 823 Phase I trials and 1,102 Phase II trials. Similar to 2024, oncology was expected to remain the leading therapeutic area, accounting for 946 trials, followed by the central nervous system with 686 trials and cardiovascular trials with 258. Therefore, the rising number of clinical trials is driving the growth of generative AI in the drug discovery market.

Major companies operating in the generative AI in the drug discovery market are developing advanced AI-powered tools to accelerate drug discovery processes. AI-powered tools streamline drug development by supporting drug discovery, design, and clinical trials through predictive analytics and machine learning. These technologies improve efficiency in areas such as target identification and compound screening, including AI-based virtual screening, preclinical development, regulatory compliance, and manufacturing processes. For instance, in May 2023, Google Cloud, a US-based cloud computing service provided by Google, introduced two innovative AI-driven solutions, the Target and Lead Identification Suite and the Multiomics Suite, to advance drug discovery and precision medicine across biotech, pharmaceutical, and public sector organizations. The Target and Lead Identification Suite helps researchers understand amino acid functions and predict protein structures, while the Multiomics Suite accelerates genomic data analysis and interpretation, simplifying the development of personalized treatments.

In May 2023, Recursion Pharmaceuticals, a US-based clinical-stage TechBio company, acquired Cyclica and Valence for $40 million and $47.5 million, respectively. Through these acquisitions, Recursion significantly strengthened its drug discovery capabilities by incorporating advanced technologies. The transactions further position Recursion as a hub for leading professionals in machine learning (ML) and artificial intelligence (AI), supporting continued innovation and advancement in drug discovery. Cyclica Inc. is a Canada-based biotechnology company specializing in data-driven drug discovery, biophysics, and artificial intelligence for developing predictive analytics software, while Valence Labs is a Canada-based AI-driven research organization focused on advancing AI applications in drug discovery.

Major companies operating in the generative artificial intelligence (AI) in drug discovery market are Bayer AG, NVIDIA Corporation, Merck KGaA, IBM Research, Schrodinger Inc., Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc., MAbSilico, Reverie Labs, Standigm Inc., DeepMatter Group Limited, Variational AI Inc

North America was the largest region in the generative AI in drug discovery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the generative artificial intelligence (AI) in drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The generative AI in drug discovery market includes revenues earned by entities by providing services such as molecule generation, optimization, virtual screening, predictive modeling, de novo drug design, and consulting support. The market value includes the value of related goods sold by the service provider or included within the service offering. The generative AI in drug discovery market also includes sales of quantum computers, high-performance computing (HPC) clusters, tensor processing units, graphics processing units, and preclinical development tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Generative Artificial Intelligence (AI) In Drug Discovery Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses generative artificial intelligence (ai) in drug discovery market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for generative artificial intelligence (ai) in drug discovery ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The generative artificial intelligence (ai) in drug discovery market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Type: Small Molecule; Large Molecule
2) By Technology: Deep Learning; Machine Learning; Reinforcement Learning; Molecular Docking; Quantum Computing
3) By End-User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutions; Contract Research Organizations (CROs); Other End-Users
Subsegments:
1) By Small Molecule: Drug Design And Optimization; Lead Discovery And Identification; Toxicology Prediction; Molecular Property Prediction; ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction
2) By Large Molecule: Protein Structure Prediction; Antibody Design; Biologics Optimization; Peptide Design; Biopharmaceutical Discovery And Optimization
Companies Mentioned: Bayer AG; NVIDIA Corporation; Merck KGaA; IBM Research; Schrodinger Inc.; Valo Health; BenevolentAI; XtalPi Inc.; Insilico Medicine Inc.; Recursion Pharmaceuticals Inc.; Exscientia; Atomwise Inc.; InveniAI LLC; Healx; Aitia; Cloud Pharmaceuticals Inc.; Optibrium; Aiforia; BioSymetrics Inc.; Collaborations Pharmaceuticals Inc.; MAbSilico; Reverie Labs; Standigm Inc.; DeepMatter Group Limited; Variational AI Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: HS6MGAIA04_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Generative Artificial Intelligence (AI) In Drug Discovery Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Generative Artificial Intelligence (AI) In Drug Discovery Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Generative Artificial Intelligence (AI) In Drug Discovery Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Generative Artificial Intelligence (AI) In Drug Discovery Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Artificial Intelligence & Autonomous Intelligence
- 4.1.2 Biotechnology, Genomics & Precision Medicine
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Sustainability, Climate Tech & Circular Economy
4.2. Major Trends
- 4.2.1 Rising Adoption Of AI-Driven Molecule Generation
- 4.2.2 Increased Use Of Deep Learning In Drug Design
- 4.2.3 Expansion Of Small Molecule Discovery Applications
- 4.2.4 Growing Integration Of AI In Lead Optimization
- 4.2.5 Accelerated Early-Stage Drug Development

5. Generative Artificial Intelligence (AI) In Drug Discovery Market Analysis Of End Use Industries

5.1 Pharmaceutical Companies
5.2 Biotechnology Companies
5.3 Contract Research Organizations
5.4 Academic Research Institutes
5.5 Drug Discovery Startups

6. Generative Artificial Intelligence (AI) In Drug Discovery Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Generative Artificial Intelligence (AI) In Drug Discovery Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Generative Artificial Intelligence (AI) In Drug Discovery PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Generative Artificial Intelligence (AI) In Drug Discovery Market Size, Comparisons And Growth Rate Analysis
7.3. Global Generative Artificial Intelligence (AI) In Drug Discovery Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Generative Artificial Intelligence (AI) In Drug Discovery Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Generative Artificial Intelligence (AI) In Drug Discovery Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Generative Artificial Intelligence (AI) In Drug Discovery Market Segmentation

9.1. Global Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Small Molecule, Large Molecule
9.2. Global Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Deep Learning, Machine Learning, Reinforcement Learning, Molecular Docking, Quantum Computing
9.3. Global Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Pharmaceutical And Biotechnology Companies, Academic And Research Institutions, Contract Research Organizations (CROs), Other End-Users
9.4. Global Generative Artificial Intelligence (AI) In Drug Discovery Market, Sub-Segmentation Of Small Molecule, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Drug Design And Optimization, Lead Discovery And Identification, Toxicology Prediction, Molecular Property Prediction, ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction
9.5. Global Generative Artificial Intelligence (AI) In Drug Discovery Market, Sub-Segmentation Of Large Molecule, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Protein Structure Prediction, Antibody Design, Biologics Optimization, Peptide Design, Biopharmaceutical Discovery And Optimization

10. Generative Artificial Intelligence (AI) In Drug Discovery Market Regional And Country Analysis

10.1. Global Generative Artificial Intelligence (AI) In Drug Discovery Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Generative Artificial Intelligence (AI) In Drug Discovery Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Generative Artificial Intelligence (AI) In Drug Discovery Market

11.1. Asia-Pacific Generative Artificial Intelligence (AI) In Drug Discovery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Generative Artificial Intelligence (AI) In Drug Discovery Market

12.1. China Generative Artificial Intelligence (AI) In Drug Discovery Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Generative Artificial Intelligence (AI) In Drug Discovery Market

13.1. India Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Generative Artificial Intelligence (AI) In Drug Discovery Market

14.1. Japan Generative Artificial Intelligence (AI) In Drug Discovery Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Generative Artificial Intelligence (AI) In Drug Discovery Market

15.1. Australia Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Generative Artificial Intelligence (AI) In Drug Discovery Market

16.1. Indonesia Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Generative Artificial Intelligence (AI) In Drug Discovery Market

17.1. South Korea Generative Artificial Intelligence (AI) In Drug Discovery Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Generative Artificial Intelligence (AI) In Drug Discovery Market

18.1. Taiwan Generative Artificial Intelligence (AI) In Drug Discovery Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Generative Artificial Intelligence (AI) In Drug Discovery Market

19.1. South East Asia Generative Artificial Intelligence (AI) In Drug Discovery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Generative Artificial Intelligence (AI) In Drug Discovery Market

20.1. Western Europe Generative Artificial Intelligence (AI) In Drug Discovery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Generative Artificial Intelligence (AI) In Drug Discovery Market

21.1. UK Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Generative Artificial Intelligence (AI) In Drug Discovery Market

22.1. Germany Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Generative Artificial Intelligence (AI) In Drug Discovery Market

23.1. France Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Generative Artificial Intelligence (AI) In Drug Discovery Market

24.1. Italy Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Generative Artificial Intelligence (AI) In Drug Discovery Market

25.1. Spain Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Generative Artificial Intelligence (AI) In Drug Discovery Market

26.1. Eastern Europe Generative Artificial Intelligence (AI) In Drug Discovery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Generative Artificial Intelligence (AI) In Drug Discovery Market

27.1. Russia Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Generative Artificial Intelligence (AI) In Drug Discovery Market

28.1. North America Generative Artificial Intelligence (AI) In Drug Discovery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Generative Artificial Intelligence (AI) In Drug Discovery Market

29.1. USA Generative Artificial Intelligence (AI) In Drug Discovery Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Generative Artificial Intelligence (AI) In Drug Discovery Market

30.1. Canada Generative Artificial Intelligence (AI) In Drug Discovery Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Generative Artificial Intelligence (AI) In Drug Discovery Market

31.1. South America Generative Artificial Intelligence (AI) In Drug Discovery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Generative Artificial Intelligence (AI) In Drug Discovery Market

32.1. Brazil Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Generative Artificial Intelligence (AI) In Drug Discovery Market

33.1. Middle East Generative Artificial Intelligence (AI) In Drug Discovery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Generative Artificial Intelligence (AI) In Drug Discovery Market

34.1. Africa Generative Artificial Intelligence (AI) In Drug Discovery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Generative Artificial Intelligence (AI) In Drug Discovery Market, Segmentation By Type, Segmentation By Technology, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Generative Artificial Intelligence (AI) In Drug Discovery Market Regulatory and Investment Landscape

36. Generative Artificial Intelligence (AI) In Drug Discovery Market Competitive Landscape And Company Profiles

36.1. Generative Artificial Intelligence (AI) In Drug Discovery Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Generative Artificial Intelligence (AI) In Drug Discovery Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Generative Artificial Intelligence (AI) In Drug Discovery Market Company Profiles
- 36.3.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. NVIDIA Corporation Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. IBM Research Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Schrodinger Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Generative Artificial Intelligence (AI) In Drug Discovery Market Other Major And Innovative Companies

Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc.

38. Global Generative Artificial Intelligence (AI) In Drug Discovery Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Generative Artificial Intelligence (AI) In Drug Discovery Market

40. Generative Artificial Intelligence (AI) In Drug Discovery Market High Potential Countries, Segments and Strategies

40.1 Generative Artificial Intelligence (AI) In Drug Discovery Market In 2030 - Countries Offering Most New Opportunities
40.2 Generative Artificial Intelligence (AI) In Drug Discovery Market In 2030 - Segments Offering Most New Opportunities
40.3 Generative Artificial Intelligence (AI) In Drug Discovery Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer